Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts
Accelerated atherosclerosis in patients with diabetes is a major cause of their morbidity and mortality, and it is unresponsive to therapy aimed at restoring relative euglycemia. In hyperglycemia, nonenzymatic glycation and oxidation of proteins and lipids results in the accumulation of irreversibly...
Gespeichert in:
| Veröffentlicht in: | Nature medicine 1998-09, Vol.4 (9), p.1025-1031 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1031 |
|---|---|
| container_issue | 9 |
| container_start_page | 1025 |
| container_title | Nature medicine |
| container_volume | 4 |
| creator | Schmidt, Ann Marie Park, Lisa Raman, Kathleen G Lee, Kenneth J Lu, Yan Ferran, Luis J Chow, Wing Sun Stern, David |
| description | Accelerated atherosclerosis in patients with diabetes is a major cause of their morbidity and mortality, and it is unresponsive to therapy aimed at restoring relative euglycemia. In hyperglycemia, nonenzymatic glycation and oxidation of proteins and lipids results in the accumulation of irreversibly formed advanced glycation endproducts. These advanced glycation endproducts engage their receptor in cells of the blood vessel wall, thereby activating mechanisms linked to the development of vascular lesions. We report here a model of accelerated and advanced atherosclerosis in diabetic mice deficient for apolipoprotein E. Treatment of these mice with the soluble extracellular domain of the receptor for advanced glycation endproducts completely suppressed diabetic atherosclerosis in a glycemia- and lipid-independent manner. These findings indicate interaction between the advanced glycation endproducts and their receptor is involved in the development of accelerated atherosclerosis in diabetes, and identify this receptor as a new therapeutic target in diabetic macrovascular disease. |
| doi_str_mv | 10.1038/2012 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73884936</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73884936</sourcerecordid><originalsourceid>FETCH-LOGICAL-c422t-6d06e68704bc00e2a867b4a5b598d9b218294a34ee5769d0adecd3526c381c143</originalsourceid><addsrcrecordid>eNpdkEtLxDAUhYMo4_MnCBHUXTXvJksRXyC4UMFdSZM7Y6WT1iQV5t-bYQYXLvIg57snnIPQMSVXlHB9zQhlO-iASqEqWpOP3XInta60kWofHab0RQjhRJoZmpmaC27kAQqv0zhGSKkbAh7m2DoHPUSbwWPf2RZy57DNnxCH5Pr13iXcrnB5wWnop7YHHMHBmIeI52VZ_2ODK9OLfuVsXttC8GMc_ORyOkZ7c9snONmeR-j9_u7t9rF6fnl4ur15rpxgLFfKEwVK10S0jhBgVqu6FVa20mhvWkY1M8JyASBrZTyxHpznkinHNXVU8CN0ufEtH39PkHKz7FJJ1tsAw5SammstDFcFPN-ArkRLEebNGLuljauGkmZda7OutWCnW7-pXYL_g7Y9Fv1io6eihAXE5muYYigR__ucbbhg8xThzycsiTG6gEzyX1dgiuk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73884936</pqid></control><display><type>article</type><title>Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>Nature Journals Online</source><creator>Schmidt, Ann Marie ; Park, Lisa ; Raman, Kathleen G ; Lee, Kenneth J ; Lu, Yan ; Ferran, Luis J ; Chow, Wing Sun ; Stern, David</creator><creatorcontrib>Schmidt, Ann Marie ; Park, Lisa ; Raman, Kathleen G ; Lee, Kenneth J ; Lu, Yan ; Ferran, Luis J ; Chow, Wing Sun ; Stern, David</creatorcontrib><description>Accelerated atherosclerosis in patients with diabetes is a major cause of their morbidity and mortality, and it is unresponsive to therapy aimed at restoring relative euglycemia. In hyperglycemia, nonenzymatic glycation and oxidation of proteins and lipids results in the accumulation of irreversibly formed advanced glycation endproducts. These advanced glycation endproducts engage their receptor in cells of the blood vessel wall, thereby activating mechanisms linked to the development of vascular lesions. We report here a model of accelerated and advanced atherosclerosis in diabetic mice deficient for apolipoprotein E. Treatment of these mice with the soluble extracellular domain of the receptor for advanced glycation endproducts completely suppressed diabetic atherosclerosis in a glycemia- and lipid-independent manner. These findings indicate interaction between the advanced glycation endproducts and their receptor is involved in the development of accelerated atherosclerosis in diabetes, and identify this receptor as a new therapeutic target in diabetic macrovascular disease.</description><identifier>ISSN: 1078-8956</identifier><identifier>EISSN: 1546-170X</identifier><identifier>DOI: 10.1038/2012</identifier><identifier>PMID: 9734395</identifier><language>eng</language><publisher>New York: Nature Publishing Group US</publisher><subject>Animals ; Arteriosclerosis - drug therapy ; Arteriosclerosis - etiology ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Cell Line ; Diabetes Mellitus, Experimental - complications ; Diabetes Mellitus, Experimental - physiopathology ; Diabetic Angiopathies - drug therapy ; Glycation End Products, Advanced - metabolism ; Humans ; Infectious Diseases ; Male ; Metabolic Diseases ; Mice ; Mice, Inbred C57BL ; Molecular Medicine ; Neurosciences ; Receptor for Advanced Glycation End Products ; Receptors, Immunologic - metabolism ; Receptors, Immunologic - therapeutic use ; Recombinant Fusion Proteins - metabolism ; Solubility ; Spodoptera ; Streptozocin</subject><ispartof>Nature medicine, 1998-09, Vol.4 (9), p.1025-1031</ispartof><rights>Nature America Inc. 1998</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c422t-6d06e68704bc00e2a867b4a5b598d9b218294a34ee5769d0adecd3526c381c143</citedby><cites>FETCH-LOGICAL-c422t-6d06e68704bc00e2a867b4a5b598d9b218294a34ee5769d0adecd3526c381c143</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/2012$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/2012$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27915,27916,41479,42548,51310</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9734395$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schmidt, Ann Marie</creatorcontrib><creatorcontrib>Park, Lisa</creatorcontrib><creatorcontrib>Raman, Kathleen G</creatorcontrib><creatorcontrib>Lee, Kenneth J</creatorcontrib><creatorcontrib>Lu, Yan</creatorcontrib><creatorcontrib>Ferran, Luis J</creatorcontrib><creatorcontrib>Chow, Wing Sun</creatorcontrib><creatorcontrib>Stern, David</creatorcontrib><title>Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts</title><title>Nature medicine</title><addtitle>Nat Med</addtitle><addtitle>Nat Med</addtitle><description>Accelerated atherosclerosis in patients with diabetes is a major cause of their morbidity and mortality, and it is unresponsive to therapy aimed at restoring relative euglycemia. In hyperglycemia, nonenzymatic glycation and oxidation of proteins and lipids results in the accumulation of irreversibly formed advanced glycation endproducts. These advanced glycation endproducts engage their receptor in cells of the blood vessel wall, thereby activating mechanisms linked to the development of vascular lesions. We report here a model of accelerated and advanced atherosclerosis in diabetic mice deficient for apolipoprotein E. Treatment of these mice with the soluble extracellular domain of the receptor for advanced glycation endproducts completely suppressed diabetic atherosclerosis in a glycemia- and lipid-independent manner. These findings indicate interaction between the advanced glycation endproducts and their receptor is involved in the development of accelerated atherosclerosis in diabetes, and identify this receptor as a new therapeutic target in diabetic macrovascular disease.</description><subject>Animals</subject><subject>Arteriosclerosis - drug therapy</subject><subject>Arteriosclerosis - etiology</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Cell Line</subject><subject>Diabetes Mellitus, Experimental - complications</subject><subject>Diabetes Mellitus, Experimental - physiopathology</subject><subject>Diabetic Angiopathies - drug therapy</subject><subject>Glycation End Products, Advanced - metabolism</subject><subject>Humans</subject><subject>Infectious Diseases</subject><subject>Male</subject><subject>Metabolic Diseases</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Molecular Medicine</subject><subject>Neurosciences</subject><subject>Receptor for Advanced Glycation End Products</subject><subject>Receptors, Immunologic - metabolism</subject><subject>Receptors, Immunologic - therapeutic use</subject><subject>Recombinant Fusion Proteins - metabolism</subject><subject>Solubility</subject><subject>Spodoptera</subject><subject>Streptozocin</subject><issn>1078-8956</issn><issn>1546-170X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkEtLxDAUhYMo4_MnCBHUXTXvJksRXyC4UMFdSZM7Y6WT1iQV5t-bYQYXLvIg57snnIPQMSVXlHB9zQhlO-iASqEqWpOP3XInta60kWofHab0RQjhRJoZmpmaC27kAQqv0zhGSKkbAh7m2DoHPUSbwWPf2RZy57DNnxCH5Pr13iXcrnB5wWnop7YHHMHBmIeI52VZ_2ODK9OLfuVsXttC8GMc_ORyOkZ7c9snONmeR-j9_u7t9rF6fnl4ur15rpxgLFfKEwVK10S0jhBgVqu6FVa20mhvWkY1M8JyASBrZTyxHpznkinHNXVU8CN0ufEtH39PkHKz7FJJ1tsAw5SammstDFcFPN-ArkRLEebNGLuljauGkmZda7OutWCnW7-pXYL_g7Y9Fv1io6eihAXE5muYYigR__ucbbhg8xThzycsiTG6gEzyX1dgiuk</recordid><startdate>19980901</startdate><enddate>19980901</enddate><creator>Schmidt, Ann Marie</creator><creator>Park, Lisa</creator><creator>Raman, Kathleen G</creator><creator>Lee, Kenneth J</creator><creator>Lu, Yan</creator><creator>Ferran, Luis J</creator><creator>Chow, Wing Sun</creator><creator>Stern, David</creator><general>Nature Publishing Group US</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19980901</creationdate><title>Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts</title><author>Schmidt, Ann Marie ; Park, Lisa ; Raman, Kathleen G ; Lee, Kenneth J ; Lu, Yan ; Ferran, Luis J ; Chow, Wing Sun ; Stern, David</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c422t-6d06e68704bc00e2a867b4a5b598d9b218294a34ee5769d0adecd3526c381c143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Animals</topic><topic>Arteriosclerosis - drug therapy</topic><topic>Arteriosclerosis - etiology</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Cell Line</topic><topic>Diabetes Mellitus, Experimental - complications</topic><topic>Diabetes Mellitus, Experimental - physiopathology</topic><topic>Diabetic Angiopathies - drug therapy</topic><topic>Glycation End Products, Advanced - metabolism</topic><topic>Humans</topic><topic>Infectious Diseases</topic><topic>Male</topic><topic>Metabolic Diseases</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Molecular Medicine</topic><topic>Neurosciences</topic><topic>Receptor for Advanced Glycation End Products</topic><topic>Receptors, Immunologic - metabolism</topic><topic>Receptors, Immunologic - therapeutic use</topic><topic>Recombinant Fusion Proteins - metabolism</topic><topic>Solubility</topic><topic>Spodoptera</topic><topic>Streptozocin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schmidt, Ann Marie</creatorcontrib><creatorcontrib>Park, Lisa</creatorcontrib><creatorcontrib>Raman, Kathleen G</creatorcontrib><creatorcontrib>Lee, Kenneth J</creatorcontrib><creatorcontrib>Lu, Yan</creatorcontrib><creatorcontrib>Ferran, Luis J</creatorcontrib><creatorcontrib>Chow, Wing Sun</creatorcontrib><creatorcontrib>Stern, David</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Nature medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schmidt, Ann Marie</au><au>Park, Lisa</au><au>Raman, Kathleen G</au><au>Lee, Kenneth J</au><au>Lu, Yan</au><au>Ferran, Luis J</au><au>Chow, Wing Sun</au><au>Stern, David</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts</atitle><jtitle>Nature medicine</jtitle><stitle>Nat Med</stitle><addtitle>Nat Med</addtitle><date>1998-09-01</date><risdate>1998</risdate><volume>4</volume><issue>9</issue><spage>1025</spage><epage>1031</epage><pages>1025-1031</pages><issn>1078-8956</issn><eissn>1546-170X</eissn><abstract>Accelerated atherosclerosis in patients with diabetes is a major cause of their morbidity and mortality, and it is unresponsive to therapy aimed at restoring relative euglycemia. In hyperglycemia, nonenzymatic glycation and oxidation of proteins and lipids results in the accumulation of irreversibly formed advanced glycation endproducts. These advanced glycation endproducts engage their receptor in cells of the blood vessel wall, thereby activating mechanisms linked to the development of vascular lesions. We report here a model of accelerated and advanced atherosclerosis in diabetic mice deficient for apolipoprotein E. Treatment of these mice with the soluble extracellular domain of the receptor for advanced glycation endproducts completely suppressed diabetic atherosclerosis in a glycemia- and lipid-independent manner. These findings indicate interaction between the advanced glycation endproducts and their receptor is involved in the development of accelerated atherosclerosis in diabetes, and identify this receptor as a new therapeutic target in diabetic macrovascular disease.</abstract><cop>New York</cop><pub>Nature Publishing Group US</pub><pmid>9734395</pmid><doi>10.1038/2012</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-8956 |
| ispartof | Nature medicine, 1998-09, Vol.4 (9), p.1025-1031 |
| issn | 1078-8956 1546-170X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73884936 |
| source | MEDLINE; Springer Nature - Complete Springer Journals; Nature Journals Online |
| subjects | Animals Arteriosclerosis - drug therapy Arteriosclerosis - etiology Biomedical and Life Sciences Biomedicine Cancer Research Cell Line Diabetes Mellitus, Experimental - complications Diabetes Mellitus, Experimental - physiopathology Diabetic Angiopathies - drug therapy Glycation End Products, Advanced - metabolism Humans Infectious Diseases Male Metabolic Diseases Mice Mice, Inbred C57BL Molecular Medicine Neurosciences Receptor for Advanced Glycation End Products Receptors, Immunologic - metabolism Receptors, Immunologic - therapeutic use Recombinant Fusion Proteins - metabolism Solubility Spodoptera Streptozocin |
| title | Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T03%3A04%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Suppression%20of%20accelerated%20diabetic%20atherosclerosis%20by%20the%20soluble%20receptor%20for%20advanced%20glycation%20endproducts&rft.jtitle=Nature%20medicine&rft.au=Schmidt,%20Ann%20Marie&rft.date=1998-09-01&rft.volume=4&rft.issue=9&rft.spage=1025&rft.epage=1031&rft.pages=1025-1031&rft.issn=1078-8956&rft.eissn=1546-170X&rft_id=info:doi/10.1038/2012&rft_dat=%3Cproquest_cross%3E73884936%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73884936&rft_id=info:pmid/9734395&rfr_iscdi=true |